The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...

Regarding who can use these inhalers, NHS guidelines state: "Most adults can use beclometasone inhalers for asthma or COPD.

Dr. Stephen Wasserman answers the question: 'What Is A Rescue Medicine?' — -- Question: What is a rescue medicine and when is it used for asthma? Answer: A rescue medicine is a medicine used in ...

Doctors have devised almost as many treatments for asthma as there are contributory causes. Victims are desensitized, kept away from substances to which they are allergic, advised to try a change of ...